Overview

Price chart · mood · technical indicators

LYEL

Lyell Immunopharma Incstock Healthcare

Biotechnology

$20.72149.22%Current Market Mood:Neutral

Market Mood

Price Range (1Y)

$7.65$45.00

Current: $20.72

Market Comparison

vs Healthcare Sector & Biotechnology Industry

LYEL

+149.22%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio—

EPS (TTM)$-16.060.0% YoY

Profit margin0.0%HEALTHCARE

Market cap$486.0MSmall cap

Wall Street coverage

$37.17median target· current $50.80 (-26.8%)4 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: —
PEG ratio: —
P/B: 1.96
P/S (TTM): 13500.46
EV/EBITDA: 0.25

Profitability & growth

ROE (TTM): -87.0%
Operating margin: -1024633.0%
Revenue growth YoY: -45.5%
Dividend yield: —
Beta: -0.06

Last earnings

Mar 13, 2026 · Estimate $-2.23 · Reported $-7.68

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Lyell Immunopharma Inc

Company profile

Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 201 HASKINS WAY, SOUTH SAN FRANCISCO, CA
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$486.0M

Shares outstanding$23.3M

52W high$45.00

52W low$7.65

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

LYEL

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

BofA Securities Maintains Lyell Immunopharma(LYEL.US) With Sell Rating, Maintains Target Price $12

LYEL SEC Filings - Lyell Immunopharma, Inc. 10-K, 10-Q, 8-K Forms

Lyell Immunopharma (NASDAQ:LYEL) Downgraded to Sell Rating by Wall Street Zen

Lyell Immunopharma (LYEL) Price Target Increased by 27.27% to 14.28

Baird initiates Lyell Immunopharma stock with outperform rating By Investing.com

Lyell Immunopharma (NASDAQ: LYEL) outlines 2026 virtual meeting, board elections and pay vote

Euler Fund (NASDAQ: LYEL) holds 1,426,528 shares, 6.71% stake disclosed

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Large Increase in Short Interest

[EFFECT] Lyell Immunopharma, Inc. SEC Filing

Lyell Immunopharma (NASDAQ:LYEL) Shares Down 4% - Should You Sell?

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives Consensus Recommendation of "Hold" from Analysts

Needham initiates coverage of Lyell Immunopharma (LYEL) with buy recommendation

Needham initiates coverage of Lyell Immunopharma (LYEL) with buy recommendation

This WhiteFiber Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Needham initiates coverage of Lyell Immunopharma (LYEL) with buy recommendation

LYEL Earnings History & Surprises | EPS & Revenue Results | LYELL IMMUNOPHARMA INC (NASDAQ:LYEL)

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

Lyell Immunopharma to Present at 25th Annual Needham Virtual Healthcare Conference

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

About Lyell Immunopharma Inc

Classification

Company profile

LYEL

Market Comparison

LYEL Market Analysis

Overview

LYEL

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

BofA Securities Maintains Lyell Immunopharma(LYEL.US) With Sell Rating, Maintains Target Price $12

LYEL SEC Filings - Lyell Immunopharma, Inc. 10-K, 10-Q, 8-K Forms

Lyell Immunopharma (NASDAQ:LYEL) Downgraded to Sell Rating by Wall Street Zen

Lyell Immunopharma (LYEL) Price Target Increased by 27.27% to 14.28

Baird initiates Lyell Immunopharma stock with outperform rating By Investing.com

Lyell Immunopharma (NASDAQ: LYEL) outlines 2026 virtual meeting, board elections and pay vote

Euler Fund (NASDAQ: LYEL) holds 1,426,528 shares, 6.71% stake disclosed

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Large Increase in Short Interest

[EFFECT] Lyell Immunopharma, Inc. SEC Filing

Lyell Immunopharma (NASDAQ:LYEL) Shares Down 4% - Should You Sell?

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives Consensus Recommendation of "Hold" from Analysts

Needham initiates coverage of Lyell Immunopharma (LYEL) with buy recommendation

Needham initiates coverage of Lyell Immunopharma (LYEL) with buy recommendation

This WhiteFiber Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Needham initiates coverage of Lyell Immunopharma (LYEL) with buy recommendation

LYEL Earnings History & Surprises | EPS & Revenue Results | LYELL IMMUNOPHARMA INC (NASDAQ:LYEL)

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

Lyell Immunopharma to Present at 25th Annual Needham Virtual Healthcare Conference

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

About Lyell Immunopharma Inc

Classification

Company profile

LYEL

Market Comparison